Literature DB >> 22377673

Proteasome inhibitors for cancer therapy.

Mohamed Iqbal1, Patricia A Messina McLaughlin, Derek Dunn, Satish Mallya, Jean Husten, Mark A Ator, Sankar Chatterjee.   

Abstract

Proteasome, a large multicatalytic proteinase complex that plays an important role in processing of proteins, has been shown to possess multiple catalytic activities. Among its various activities, the 'chymotrypsin-like' activity of proteasome has emerged as the focus of drug discovery efforts in cancer therapy. Herein we report chiral boronate derived novel, potent, selective and cell-permeable peptidomimetic inhibitors 6 and 7 that displayed activity against various rodent and human tumor cell lines (in vitro).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377673     DOI: 10.1016/j.bmc.2012.02.007

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Eri Inami; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Fumi Utsumi; Kaoru Niimi; Shiro Suzuki; Kiyosumi Shibata; Akihiro Nawa; Fumitaka Kikkawa
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

2.  Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells.

Authors:  Sihan Lin; Zhiyong Yan; Qiaofei Tang; Shuang Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.